Compositions and methods for targeting type 1 interferon producing cells
AssigneeCSL Limited
InventorsGino Luigi VAIRO, Andrew NASH, Eugene MARASKOVSKY, Nick WILSON, Samantha BUSFIELD
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.
Claims27
-30. (canceled)
A method of treating lupus in a mammal, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and competitively inhibits the binding of monoclonal antibody 7G3 to IL-3Rα and which depletes or at least partly eliminates plasmacytoid dendritic cells (pDCs) and basophils to which it binds to thereby treat lupus in the mammal, wherein the immunoglobulin is not conjugated to a toxic compound that kills a cell to which the immunoglobulin binds, and wherein the immunoglobulin is capable of inducing an enhanced level of effector function.
A method of treating lupus in a mammal, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (pDCs) and basophils to which it binds to thereby treat lupus in the mammal, wherein the immunoglobulin is not conjugated to a toxic compound that kills a cell to which the immunoglobulin binds, and wherein the immunoglobulin is capable of inducing an enhanced level of effector function.
Dependencies are inferred from the claim text.